An Open Label Phase II Study of Tipifarnib in Advanced Squamous Non-small Cell Lung Cancer With HRAS Mutations

Trial Profile

An Open Label Phase II Study of Tipifarnib in Advanced Squamous Non-small Cell Lung Cancer With HRAS Mutations

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Aug 2018

At a glance

  • Drugs Tipifarnib (Primary)
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 06 Aug 2018 Status changed from not yet recruiting to recruiting, according to Kura oncology media release.
    • 06 Aug 2018 According to a Kura Oncology media release the dosing of the first patient is done.
    • 08 May 2018 According to a Kura Oncology media release, this trial will be initiated later in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top